1-20 of 28
Tae Min Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies

Tae Min Kim, Dok Hyun Yoon, Ahmad H. Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, Seok Jin Kim
Journal: Blood
Blood (2021) 138 (Supplement 1): 3562.
DOI: https://doi.org/10.1182/blood-2021-149927
Published: 2021
Journal Articles

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Burhan Ferhanoglu, Marta Zerga, Mubarak Al-mansour, Tae Min Kim, Su-Peng Yeh, Yuqin Song, Amado J Karduss, Gayane Tumyan, Soon Thye Lim, Silvia Rivas-Vera, Yok Lam Kwong, Kwang-Wei Wu, Zhongwen Huang, Mark Hertzberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 1397.
DOI: https://doi.org/10.1182/blood-2021-145838
Published: 2021
Journal Articles

Low Density of CD3+ Tumor-Infiltrating Lymphocytes Is Predictive of a Poor Prognosis in Diffuse Large B-Cell Lymphoma Independently of MYC and BCL2 Double Expression Status: A Potential Utility of Immunoscore Based on Whole-Slide Image Analysis

Bogyeong Han, Jeemin Yim, Sojung Lim, Cheol Lee, Tae Min Kim, Kim Sehui, Yoon Kyung Jeon
Journal: Blood
Blood (2021) 138 (Supplement 1): 2523.
DOI: https://doi.org/10.1182/blood-2021-154204
Published: 2021
Journal Articles

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Adam J Olszewski, MD, Javier Munoz, MD, Tae Min Kim, MD PhD, Dok Hyun Yoon, Richard Greil, MD, Jason Westin, MD, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O'Hear, Raluca Negricea, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, Anusha Vallurupalli
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
DOI: https://doi.org/10.1182/blood-2020-136295
Published: 2020
Journal Articles

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Burhan Ferhanoglu, MD, Tae Min Kim, MD PhD, Amado Karduss, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Gayane Tumyan, Mubarak Al Mansour, Marta Zerga, MD, Yuqin Song, MD PhD, Silvia Rivas-Vera, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, Su-Peng Yeh, MD, Arif Abdillah, MD, Zhongwen Huang, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg, MBBS PhDFRACP FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
DOI: https://doi.org/10.1182/blood-2020-134885
Published: 2020
Journal Articles

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Alison J. Forgie, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MDPhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
DOI: https://doi.org/10.1182/blood-2020-135941
Published: 2020
Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
DOI: https://doi.org/10.1182/blood-2020-137078
Published: 2020
Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Arancha Alonso, MD, Miles Prince, MD, Michal Taszner, MD, Seok-Goo Cho, MD, PhD, Don A. Stevens, MD, Michelle Poon, MD, Francesca Lim, MBBS, BSc, MRCP (UK), Steven Le Gouill, MD PhD, Cecilia Carpio, MD, Mary-Margaret Keating, MD FRCPC, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ayesha Sabir, BSc, Jingjin Li, PhD, Vladimir Jankovic, MD, Min Zhu, PhD, Jurriaan Brouwer-Visser, PhD, Siyang Leng, MD MS, L. Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Kim Won Seog, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
DOI: https://doi.org/10.1182/blood-2020-136344
Published: 2020
Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Hui-qiang Huang, Won-Seog Kim, MD PhD, Ming Yao, MD, Tae Min Kim, MD PhD, DocHyun Yoon, MD PhD, Seok-Goo Cho, MD PhD, Hyeon-Seok Eom, MD PhD, Su-Peng Yeh, MD, Soon Thye Lim, MBBS, MRCP, FAMS, Yuqin Song, Shizhou Liu, MD, Grace Gao, Lijia Zhang, Min Qing, Ming Qi, MD PhD, Jin Seok Kim, MD PhD, Yok Lam Kwong, MD FRCP, Jie Jin, MD PhD, Yuankai Shi, MD PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1568.
DOI: https://doi.org/10.1182/blood-2019-123446
Published: 2019
Journal Articles

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MD PhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1953.
DOI: https://doi.org/10.1182/blood-2019-123219
Published: 2019
Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4081.
DOI: https://doi.org/10.1182/blood-2019-123449
Published: 2019
Journal Articles

Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC)

Burhan Ferhanoglu, MD, Tae Min Kim, Gayane Tumyan, DMSc, MD PhD, Su-Peng Yeh, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Amado Karduss, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, FAMS, Mubarak Al Mansour, MD, Silvia Rivas-Vera, MD, Yuqin Song, MD PhD, Marta Zerga, MD, Julie Blair, PhD MD MPhil, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg
Journal: Blood
Blood (2018) 132 (Supplement 1): 2917.
DOI: https://doi.org/10.1182/blood-2018-99-111146
Published: 2018
Journal Articles

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Laurie H Sehn, MDMPH, Alex F. Herrera, MD, Matthew J Matasar, Manali Kamdar, Sarit Assouline, Mark Hertzberg, Tae Min Kim, Won-Seog Kim, Andrew McMillan, Muhit Özcan, Jamie M Hirata, Elicia Penuel, Ji Cheng, Grace Ku, Christopher R Flowers, MDMS
Journal: Blood
Blood (2018) 132 (Supplement 1): 1683.
DOI: https://doi.org/10.1182/blood-2018-99-118551
Published: 2018
Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim
Journal: Blood
Blood (2017) 130 (Supplement 1): 4128.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128
Published: 2017
Journal Articles

Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

Laurie H. Sehn, MDMPH, Alex F. Herrera, MD, Matthew J. Matasar, MD, Manali Kamdar, Andrew K. McMillan, FRCP, Tae Min Kim, Won Seog Kim, MD, Ph. D., Mark Hertzberg, MBBS, PhD, Muhit Ozcan, MD, Elicia Penuel, Ji Cheng, Jamie M. Hirata, Grace Ku, Christopher Flowers, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2821.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2821.2821
Published: 2017
Journal Articles

Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study

Mathias J Rummel, Tae Min Kim, Franco Aversa, MD, Wolfram Brugger, MDPhD, Enrico Capochiani, Caterina Plenteda, Francesca Re, Peter Task, Christine McIntyre, Oliver Meier, Stuart Osborne, Rodney Smith, Andrew Grigg, MBBS FRACP FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 2834.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2834.2834
Published: 2017
Journal Articles

Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Alex F Herrera, MD, Matthew J. Matasar, MD MS, Sarit Assouline, Manali Kamdar, MD, Amitkumar Mehta, MD, Isabelle Fleury, MD, Won Seog Kim, Tae Min Kim, MD PhD, Francesc Bosch, MD PhD, John A Radford, MBChB, MRCP, MD FRCP, Lilian Bu, MS, Wan-Jen Hong, MD, Laurie H Sehn, MD
Journal: Blood
Blood (2016) 128 (22): 4194.
DOI: https://doi.org/10.1182/blood.V128.22.4194.4194
Published: 2016
Journal Articles

Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience

Ja Min Byun, Jeong-Ok Lee, Tae Min Kim, MD PhD, Bhumsuk Keam, Dae Seog Heo, Ki Hwan Kim, Soo-Mee Bang, Jong Seok Lee
Journal: Blood
Blood (2016) 128 (22): 4222.
DOI: https://doi.org/10.1182/blood.V128.22.4222.4222
Published: 2016
Journal Articles

Prefmab: Final Analysis of Patient Preference for Subcutaneous Versus Intravenous Rituximab in Previously Untreated CD20+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Mathias Rummel, MD PhD, Tae Min Kim, MD PhD, Caterina Plenteda, MD, Enrico Capochiani, MD, Maria Mendoza, Rodney Smith, MD PhD, Stuart Osborne, MSc, Andrew Grigg, MBBS, MD FRACP, FRACPA
Journal: Blood
Blood (2015) 126 (23): 3972.
DOI: https://doi.org/10.1182/blood.V126.23.3972.3972
Published: 2015
Journal Articles

Ceritinib in patients with advanced anaplastic lymphoma kinase–rearranged anaplastic large-cell lymphoma

Clinical Trials & Observations
Heike Richly, Tae Min Kim, Martin Schuler, Dong-Wan Kim, Simon J. Harrison, Alice T. Shaw, Anthony L. Boral, Alejandro Yovine, Benjamin Solomon
Journal: Blood
Blood (2015) 126 (10): 1257–1258.
DOI: https://doi.org/10.1182/blood-2014-12-617779
Published: 2015